

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)



Europäisches Patentamt
European Patent Office
Office européen des brevets

⑪ Publication number:

0 318 081
A1

⑫

EUROPEAN PATENT APPLICATION

⑬ Application number: 88202555.4

⑭ Int. Cl. 4: A61K 47/00, A61K 39/395

⑮ Date of filing: 16.11.88

⑯ Priority: 27.11.87 NL 8702848

⑰ Date of publication of application:
31.05.89 Bulletin 89/22

⑲ Designated Contracting States:
AT BE CH DE ES FR GB GR IT LI LU NL SE

⑳ Applicant: AKZO N.V.
Velperweg 76
NL-6824 BM Arnhem(NL)

㉑ Inventor: Jansen, Theodorus
Bachstraat 81
NL-5802 GP Venray(NL)
Inventor: Janssen, Engelbertus Johannes
Maria
Vijverweg 15
NL-6562 ZL Groesbeek(NL)
Inventor: Cornelius, Lammert
Sweelink 35
NL-5831 KP Boxmeer(NL)

㉒ Representative: Hermans, Franciscus G.M. et
al
Patent Department AKZO N.V. Pharma
Division P.O. Box 20
NL-5340 BH Oss(NL)

㉓ **Stabilization of antibodies.**

㉔ According to the present invention antibody preparations are more stable during storage if in addition they contain a mixture of at least one polyoxypropylene-polyoxyethylene block polymer (such as Pluronic F68) and at least one phospholipid (such as lecithin).

EP 0 318 081 A1

Stabilization of antibodies

This application relates to a stable aqueous solution of antibodies.

To an increasing extent, antibodies are being used in human and in veterinary medicine both for prophylactic and for diagnostic and therapeutic purposes. The antibodies used in this manner are at present primarily monoclonal antibodies which can be obtained with high purity from a culture of immortalized B-lymphocytes.

Important fields of application for antibodies are, inter alia, the prevention or cure of infectious diseases (for which, for example, antiviral, antibacterial or antiparasitic antibodies are administered) the regulation of hormone levels (in particular, of gonadotropins, for which anti-gonadotropins are administered) and the localization and/or combating of tumours (for which antibodies, optionally bonded to a labelling substance or therapeutic agent, directed against specific tumour antigens are administered).


In all these applications, the problem is to keep the aqueous solution of the antibodies stable for a sufficiently long time, not only with respect to the activity but, in particular, also with respect to the physical state of the antibody molecules. This physical instability of antibody solutions often results in aggregate formation and, in the long term, in sedimentation of the antibodies. As a result of this, constant quality of the product cannot be guaranteed, which is unacceptable for pharmaceutical products.

It has now been found that aqueous solutions of antibodies are physically stable for a sufficiently long time if they also contain a combination of a polyoxypropylene-polyoxyethylene block polymer (POP-POE block polymer) and a phospholipid.

20 No aggregation of the antibodies occurs in such a composition so that the solution remains clear and homogeneous while the activity of the peptide also remains intact.

The POP-POE block polymers, also termed poloxamers, are marketed under trade names such as Pluronic^(R), Synperonic^(R), Supronic^(R) and Emkalyx^(R). These are compounds which consist of blocks of polyoxypropylene

25



30

and polyoxyethylene (POE) $[(CH_2-CH_2-O)_y]$ (wherein x and y are integers) which respectively form the hydrophobic and hydrophilic components of such block polymers. Known block polymer compounds are of the normal three-block type:

HO-[POE]-[POP]-[POE]-H


35

which include the Pluronics L31, L81, L92, L101, L131, L122, P103, F68 and F108, or of the reverse three-block type:

HO-[POP]-[POE]-[POE]-H


which include the Pluronics 25R1 and 31R1, or of the normal eight-block type:

40



which include the Pluronics T1101, T1301 and T1501, or of the reverse eight-block type:

45



50 represented by, inter alia, the Pluronics T90R1, T110R1, T130R1, T130R2, T150R1, T150R4 and T150R8.

The difference between these four types stems from the differences in average chain length of the respective POP and POE blocks.

In general, use is preferably made of POP-POE three-block polymers having a mean molecular weight between approximately 950 and 4,000 and having a polyoxyethylene content of up to approximately 80%.

Within the scope of the present invention, the most suitable representatives have, in view of their water solubility, a POE content of greater than 50%, such as, for example, Pluronic F68.

The phospholipids are esters of phosphoric acid and occur, *inter alia*, in lecithin. The quantitative composition of lecithin varies depending on the source. The phospholipids in lecithin comprise tens of compounds, of which the most important are phosphatidyl choline, phosphatidyl ethanolamine and phosphatidyl inositol. In addition, phosphatidyl serine, diphosphatidyl glycerol, sphingomyelin, phosphatidic acid and lysophospholipids. These components can be obtained in more or less pure form from lecithin, but if desired, they can also be prepared synthetically. According to the present invention, the aqueous antibody solution may contain, for example, lecithin, or a fraction thereof, or a component thereof or a mixture of two or more of these components. Advantageously, use can be made of a mixture which consists mainly of phosphatidyl choline and phosphatidyl ethanolamine (preferably, at least approximately 90%) and small quantities of phosphatidyl inositol and lysophospholipids.

The quantity of block polymer in the solution according to the invention is preferably between 0.01 and 5%, the quantity of phospholipids preferably between 0.0001 and 1%, and the concentration of antibodies is 15 preferably between 0.001 and 1 mg/ml.

The antibodies which can be stabilized according to the present invention may, for example, consist of, or be obtained from, antiserum (polyclonal antibodies) or be produced by immortalized B-lymphocytes (monoclonal antibodies), or possibly by triomas or quadromas (which produce bivalent monoclonal antibodies) or by preferably eukaryotic host cells which have been transformed with recombinant DNA, at least 20 a part of which codes for a (possibly chimaeric) antibody or an antigen-bonding fragment thereof.

The relevant antibodies may be directed against any antigen or hapten of, for example, diagnostic, prognostic, therapeutic or prophylactic importance. Suitable antigens are, for example, directed against hormones and, in particular, against gonadotropic hormones such as human chorionic gonadotropin, follicle-stimulating hormone, luteinizing hormone, "pregnant mare serum gonadotropin" (PMSG), and human 25 menopausal gonadotropin.

In livestock breeding, PMSG is used to promote pregnancy, and specifically, the number of offspring. Antibodies for PMSG (anti-PMSG) are then administered after some time to eliminate the disadvantageous effects of a high PMSG content in the blood for the fertilized egg cell.

The invention is explained by reference to the following examples.

30

Example 1

	Monoclonal anti-PMSG	(R)	880	μg
	Phospholipid mixture (Infusol)		10	μg
35	Pluronic F68		3	mg
	Glycine		7.06	mg
	Benzyl alcohol		10	mg
40	Water for injection to make		1	ml

45

50

55

Example 2

5	Monoclonal anti-PMSC	(R)	200	μg
	Phospholipid mixture (Infusol)		10	μg
	Pluronic F68		6	mg
	Glycine		7.06	mg
10	Benzyl alcohol		10	mg
	Water for injection to make		1	ml

Example 3

15	Monoclonal anti-HCG		0.75	mg
	Phospholipon 100		100	μg
	Pluronic F87		1	mg
20	Phosphate buffer, 0.07 M, pH = 8		0.9	ml
	Water for injection to make		1	ml

Example 4

25	Monoclonal anti-K99		0.85	mg
	Phospholipon 100		100	μg
	Pluronic F38		1	mg
30	Thiomersal		0.1	mg
	Glucose		100	mg
	Phosphate buffer, 0.05 M, pH = 7		0.8	ml
	Purified water to make		1	ml

35

Example 5

40	Monoclonal anti-PST (porcine somatotropin)		3.0	mg
	Epicuron 125		0.5	mg
	Pluronic L121		10	mg
	Carbonate buffer 0.05M pH = 8.5		0.6	ml
45	Water for injection	ad	1	ml

50

55

Example 6

5	Monoclonal anti-GnRH	2.5	mg
	Infusol	50	µg
	Pluronic F38	1	mg
	Glycocol	7.5	mg
	Benzylalcohol	10	mg
10	Water for injection	ad	1 ml

Example 7

15	Monoclonal anti-inhibin	1.0	mg
	Lecithin	10	mg
	Pluronic L121	50	mg
	Phosphate buffer pH = 6	0.6	ml
20	Methylparaten	1.0	mg
	Water for injection	ad	1 ml

25 The stability and activity of the antibody solutions described in Examples 1 and 2 have been studied for many months. At the same time, they were compared with solutions which contained no POP-POE block polymer and phospholipid. The results are shown in the table below:

30

35

40

45

50

55

Preparation No.	7900 Monoclonal 167 µg/ml; benzyl alcohol; 1% glycine buffer		8285 Monoclonal 167 µg/ml; gelatin A 0.1%; benzyl alcohol 1%; glycine buffer		8488 (Example 1) Monoclonal 880 µg/ml; Infusol 0.001%; Pluronic F68 0.3%; benzyl alcohol 1%; glycine buffer		8984 (Example 2) Monoclonal 200 µg/ml; Infusol 0.001%; Pluronic F68 0.6%; benzyl alcohol 1%; glycine buffer		9566 Monoclonal 200 µg/ml; Infusol 0.001%; Pluronic F68 0.3%; benzyl alcohol 1%; glycine buffer							
	Physical stability	4 °C	25 °C	37 °C	4 °C	25 °C	37 °C	4 °C	25 °C	37 °C	4 °C	25 °C	37 °C	4 °C	25 °C	37 °C
T ₀	+	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+
1 week	+	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+
2 weeks	+	+	+	-	+	+	+	+	+	+	+	+	+	+	+	+
1 month	+	+	+	-	+	+	-	-	-	-	-	-	-	-	-	-
2 months	±	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
3 months	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
6 months	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
9 months	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12 months	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
18 months	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Key:

- + completely clear when assessed in shadow position
- ± one or more particles visible
- several particles visible on sedimentation

Activity IU/ml	T ₀	1 week	2 weeks	1 month	2 months	3 months	6 months	9 months	12 months	18 months	
		1040	1030	1020	-	1410	-	1368	-	-	
		980	940	700	940	1130	960	1040	1296	1230	
		1040	1010	940	940	1300	1160	940	1248	1152	
		1000	1000	940	6400	6000	6400	1040	1128	1164	
		1040	990	910	5040	5400	5400	1160	1296	1080	
					6600	6060	4440	1512	1248	1044	
							1296	1128	1440	912	
							1272	876	252	486	
									1212	972	392

Claims

5

1. Stable aqueous solution of antibodies, characterized in that it also contains a combination of polyoxypropylene-polyoxyethylene block polymer and phospholipid.
2. Aqueous solution according to claim 1, characterized in that it contains a polyoxypropylene-polyoxyethylene block polymer having a molecular weight between 950 and 4,000 daltons.
- 10 3. Aqueous solution according to claim 1 or 2, characterized in that it contains a polyoxypropylene-polyoxyethylene block polymer in which the polyoxyethylene content is at most 80%.
4. Aqueous solution according to claim 3, characterized in that it contains a polyoxypropylene-polyoxyethylene block polymer in which the polyoxyethylene content is at least 50%.
- 15 5. Aqueous solution according to claims 1-4, characterized in that it contains lecithin as phospholipid.
6. Aqueous solution according to claims 1-5, characterized in that it contains 0.01-5% polyoxypropylene-polyoxyethylene block polymer.
7. Aqueous solution according to claims 1-6, characterized in that it contains 0.0001-1% phospholipid.
8. Aqueous solution according to claims 1-7, characterized in that it contains 0.001-1 mg of antibody/ml.

20

25

30

35

40

45

50

55



EP 88 20 2555

DOCUMENTS CONSIDERED TO BE RELEVANT															
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 4)												
Y	BIOLOGICAL ABSTRACTS, vol. 82, 1986, abstract no. 37564 Philadelphia, PA, US; S. BENITA et al.: "Physostigmine emulsion; A new injectable controlled release delivery system" & INT J PHARM (AMST) 30(1): 47-56 1986 * Abstract * ---	1-8	A 61 K 47/00 A 61 K 39/395												
Y	EP-A-0 085 747 (SCHWEIZERISCHES SERUM-UND IMPFINSTITUT UND INSTITUT ZUR ERFORSCHUNG DER INFektionsKRANKHEITEN) * Page 12, line 28 - page 13, line 7; claims 1-4 *	1-8													
Y	EP-A-0 095 751 (EISAI & CO.) * Page 7, lines 7-11; claims 1-10 *	1-8													
Y	EP-A-0 231 039 (DE STAAT DER NEDERLANDEN) * Claims 1-14 *	1-8													
			TECHNICAL FIELDS SEARCHED (Int. Cl. 4)												
			A 61 K												
<p>The present search report has been drawn up for all claims</p> <table border="1"> <tr> <td>Place of search THE HAGUE</td> <td>Date of completion of the search 23-12-1988</td> <td>Examiner BERTE M.J.</td> </tr> <tr> <td colspan="3">CATEGORY OF CITED DOCUMENTS</td> </tr> <tr> <td colspan="3"> X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document </td> </tr> <tr> <td colspan="3"> T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document </td> </tr> </table>				Place of search THE HAGUE	Date of completion of the search 23-12-1988	Examiner BERTE M.J.	CATEGORY OF CITED DOCUMENTS			X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document		
Place of search THE HAGUE	Date of completion of the search 23-12-1988	Examiner BERTE M.J.													
CATEGORY OF CITED DOCUMENTS															
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document															
T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document															